ARTICLE | Product Development

National Academies tasks all parties with improving clinical trial diversity

The Academies’ 17-part plan involves industry, journals, FDA, CMS and more. The cost of not acting will reach hundreds of billions, it says.

May 26, 2022 12:39 AM UTC

A National Academies report finds lack of representation in clinical research compounds health disparities, hinders innovation and costs the U.S. hundreds of billions of dollars. No single actor in the research enterprise can fix the problem, argues the Academies, which makes 17 recommendations aimed at mobilizing all stakeholders. 

“The problem of lack of representation in clinical research is the result of a systemic failure that will require a paradigm shift with the involvement of every constituent in the research enterprise to solve, from individual researchers to institutions, to regulators, to funders,” study committee member Susan Schaeffer, who is founder, president and CEO of The Patients’ Academy for Research Advocacy, told BioCentury...